Precigen, Inc.
PGEN Healthcare Biotechnology
Precigen, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.7 million, up 146.7% from fiscal 2024. In the quarter to June 2026, revenue grew 6,322.7%, EPS grew 166.7% and free cash flow grew 8.73%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow PGEN
Precigen, Inc. (PGEN) Altman Z-score
Precigen, Inc.'s Altman Z-score for fiscal 2025 is −16.93, in the distress zone (below 1.81).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | −16.93 | 3.30 |
| FY2024 | −20.23 | (6.29) |
| FY2023 | −13.94 | (3.05) |
| FY2022 | −10.89 | (4.78) |
| FY2021 | −6.11 | (1.73) |
| FY2020 | −4.38 | 0.09 |
| FY2019 | −4.47 | (2.26) |
| FY2018 | −2.21 | (3.56) |
| FY2017 | 1.35 | (2.11) |
| FY2016 | 3.46 | (2.94) |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.50 | — | 0.60 | |
| Retained earnings / total assets | (15.06) | — | −21.08 | |
| EBIT / total assets | (0.71) | — | −2.35 | |
| Market value of equity / total liabilities | 9.72 | — | 5.83 | |
| Sales / total assets | 0.06 | — | 0.06 | |
| Altman Z-score | Distress zone | −16.93 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −50.41 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| NAMS NewAmsterdam Pharma Company N.V. compare | 27.6× |
| ADMA ADMA Biologics Inc compare | 20.0× |
| BEAM Beam Therapeutics Inc. compare | 5.4× |
| NRIX Nurix Therapeutics, Inc. compare | 3.8× |
| ZLAB Zai Lab Limited Unsponsored ADR compare | −0.2× |
| PGEN Precigen, Inc. | −16.9× |
| MBX MBX Biosciences, Inc. compare | — |
| DYN Dyne Therapeutics, Inc. compare | — |
| ELVN Enliven Therapeutics, Inc. compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets